Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2012

Conditions
Cervical Squamous Cell CarcinomaRecurrent Cervical Carcinoma
Interventions
BIOLOGICAL

Cetuximab

Given IV

Trial Locations (22)

10065

Memorial Sloan-Kettering Cancer Center, New York

11718

Island Gynecologic Oncology, Brightwaters

11794

Stony Brook University Medical Center, Stony Brook

19001

Abington Memorial Hospital, Abington

27599

University of North Carolina, Chapel Hill

28203

Carolinas Medical Center, Charlotte

29621

AnMed Health Hospital, Anderson

39581

Singing River Hospital, Pascagoula

43214

Riverside Methodist Hospital, Columbus

44109

MetroHealth Medical Center, Cleveland

44307

Akron General Medical Center, Akron

46260

Saint Vincent Hospital and Health Services, Indianapolis

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

62526

Decatur Memorial Hospital, Decatur

65807

CoxHealth South Hospital, Springfield

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74104

Cancer Care Associates-Midtown, Tulsa

74146

Tulsa Cancer Institute, Tulsa

77030

M D Anderson Cancer Center, Houston

80010

Colorado Gynecologic Oncology Group, Aurora

06050

The Hospital of Central Connecticut, New Britain

02905

Women and Infants Hospital, Providence

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter